Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT06304168
Status
Recruiting
Apply to this trial

Conditions

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Non-Interventional Study — OTHER
    Non-interventional study

Study Details

This study explores the potential value of a new blood test approach for early detection of cancer.

Key Dates

Start date
May 13, 2019
Status verified
Feb 2026
Primary completion
May 15, 2028
Completion
May 15, 2028

Study Design

Enrollment
6,150 participants (estimated)

Arms

  • Arm: Observational
    Patients undergo blood, urine, and/or residual tissue sample collection and have their medical records reviewed on study.

Primary Outcome Measure

Overall cancer (Y/N) - blood test [ Time Frame: Baseline (samples collected at enrollment) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905
Clinical Trials Referral Office
[email protected]
855-776-0015
John B. Kisiel, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies